SCHEMBL49711

SCHEMBL49711

Oc1cc(-c2ccccc2)c(P)c(-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.60
PDE4B Q07343 3/20 0.51
PDE4A P27815 2/20 0.51
PDE4C Q08493 2/20 0.51
PDE4D Q08499 2/20 0.51
ALOX5 P09917 2/20 0.47
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
BCL2L1 Q07817 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ESR2 Q92731 4/20 0.42
ESR1 P03372 3/20 0.42
HTT P42858 1/20 0.42
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2B6 P20813 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49916 0.86 BACE1 (0.58) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL21382004 0.83 BACE1 (0.65) BACE1PDE4BPDE4APDE4CPDE4D
Phosphine SCHEMBL1744080 0.81 BACE1 (0.62) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL28096487 0.81 BACE1 (0.62) BACE1PDE4BPDE4APDE4CPDE4D
Methane SCHEMBL28838467 0.81 BACE1 (0.62) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL1760415 0.81 PDE4B (0.62) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL6521502 0.80 BACE1 (0.61) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL6669018 0.79 BACE1 (0.60) BACE1PDE4BPDE4APDE4CPDE4D
Ethylene SCHEMBL28403381 0.79 BACE1 (0.60) BACE1PDE4BPDE4APDE4CPDE4D
Ethane SCHEMBL27486393 0.79 BACE1 (0.60) BACE1PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129467-B2 Curing accelerating compound-silica composite material, method for producing curing accelerating compound-silica composite material, curing accelerator, curable resin composition, and electronic component device HITACHI CHEMICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE HITACHI CHEMICAL CO., LTD. (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE NCAPH, RAD51, H1-2 BACE1 3265/4885PDE4B 4764/4885PDE4A 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.